CIK 0001390478 · Non-accelerated filer<br>Smaller reporting company
SELLAS Life Sciences Group, Inc.
Sign in to watch- Ticker
- SLS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 6462005278
- Business address
- 7 TIMES SQUARE, SUITE 2503, NEW YORK, NY, 10036
- Former names
- GALENA BIOPHARMA, INC., Galena Biopharma, Inc., RXI PHARMACEUTICALS CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-11-19 | Kalin Katherine Bach Director | Purchase | +63,400 | $1.59 | $101K | 104,400 |
| 2025-06-12 | VAN NOSTRAND ROBERT L Director | Purchase | +10,000 | $1.48 | $15K | 20,400 |
| 2025-05-30 | Wasman Jane Director | Purchase | +20,000 | $1.69 | $34K | 30,400 |
| 2025-05-22 | Kalin Katherine Bach Director | Purchase | +20,000 | $1.80 | $36K | 41,000 |
Page 1 of 1 · 4 trades